[Skip to Navigation]
Invited Commentary
March 18, 2019

Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B

Author Affiliations
  • 1Division of General Internal Medicine, School of Medicine, University of California, San Francisco
  • 2Department of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven
  • 3Division of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut
  • 4Division of Gastroenterology, School of Medicine, University of Pennsylvania Philadelphia
  • 5Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
JAMA Intern Med. 2019;179(5):640-641. doi:10.1001/jamainternmed.2018.8314

Liver cancer (hepatocellular carcinoma [HCC]) incidence and mortality rates have been increasing in most countries for several decades. Currently, HCC is the second most common cause of cancer-related death in the world and represents the fastest rising cause of cancer-related deaths in the United States.1 Chronic hepatitis B virus (HBV) and hepatitis C virus are the primary underlying causes of HCC, with contributions from alcohol, tobacco, aflatoxin, obesity, and metabolic syndrome. In patients with chronic hepatitis C virus, the risk of HCC can be reduced rapidly with short-term, direct-acting antiviral medications. In chronic HBV, oncogenesis starts with viral DNA integration into the genome of host hepatocytes that induces a cascade of host responses, including cell injury, necrosis, and angiogenesis, reflected clinically by the levels of serum alanine aminotransferase and HBV DNA, both of which are predictors of HCC.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×